Medicure Inc.

Medicure Inc., a biopharmaceutical company provides the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia.

Additionally, it is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological indications, such as Tardive Dyskinesia. It offers products through retail and mail order, and online pharmacies. Founded in 1997, the company is headquartered in Winnipeg, Canada.